Cumberland Pharmaceuticals (NASDAQ: CPIX) reported Q1 EPS of ($0.12), $0.14 worse than the analyst estimate of $0.02. Revenue for the quarter came in at $8.33 million versus the consensus estimate of $9.46 million.

"Our thoughts go out to those currently suffering from the novel coronavirus pandemic, and we extend our sincere gratitude to those on the front lines treating patients and performing essential jobs that allow our society to function," said A.J. Kazimi, Chief Executive Officer of Cumberland Pharmaceuticals. "Cumberland has remained open during this pandemic, since we are considered to be an essential business by the United States Department of Homeland Security. We have faced the same headwinds that have affected many healthcare companies, but we have implemented measures to lessen the impact of the coronavirus on our company during 2020."

For earnings history and earnings-related data on Cumberland Pharmaceuticals (CPIX) click here.